DTaP with or without 7-valent pneumococcal conjugate vaccine in healthy Japanese infants

Phase 4, randomised, open-label trial of diphtheria, tetanus, and acellular pertussis vaccine and pneumococcal 7-valent conjugate vaccine in pneumococcal disease, diphtheria, Tetanus and 1 more (2 arms), sponsored by Pfizer. Primary endpoint: Percentage of subjects achieving predefined antibody levels for diphtheria toxoid, tetanus toxoid, pertussis toxin, and filamentous haemagglutinin 1 month after the infant series.